JP2013501056A5 - - Google Patents

Download PDF

Info

Publication number
JP2013501056A5
JP2013501056A5 JP2012523680A JP2012523680A JP2013501056A5 JP 2013501056 A5 JP2013501056 A5 JP 2013501056A5 JP 2012523680 A JP2012523680 A JP 2012523680A JP 2012523680 A JP2012523680 A JP 2012523680A JP 2013501056 A5 JP2013501056 A5 JP 2013501056A5
Authority
JP
Japan
Prior art keywords
use according
compound
polyomavirus
subject
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012523680A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013501056A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/044093 external-priority patent/WO2011017253A1/en
Publication of JP2013501056A publication Critical patent/JP2013501056A/ja
Publication of JP2013501056A5 publication Critical patent/JP2013501056A5/ja
Pending legal-status Critical Current

Links

JP2012523680A 2009-08-03 2010-08-02 ウイルス感染およびウイルス誘発腫瘍を治療する組成物および方法 Pending JP2013501056A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US23093109P 2009-08-03 2009-08-03
US61/230,931 2009-08-03
PCT/US2010/044093 WO2011017253A1 (en) 2009-08-03 2010-08-02 Composition and methods of treating viral infections and viral induced tumors

Publications (2)

Publication Number Publication Date
JP2013501056A JP2013501056A (ja) 2013-01-10
JP2013501056A5 true JP2013501056A5 (enExample) 2013-09-12

Family

ID=43544613

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012523680A Pending JP2013501056A (ja) 2009-08-03 2010-08-02 ウイルス感染およびウイルス誘発腫瘍を治療する組成物および方法

Country Status (7)

Country Link
US (1) US20120164104A1 (enExample)
EP (1) EP2462152A4 (enExample)
JP (1) JP2013501056A (enExample)
AU (1) AU2010279678B2 (enExample)
BR (1) BR112012002551A2 (enExample)
CA (1) CA2770282A1 (enExample)
WO (1) WO2011017253A1 (enExample)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006110655A2 (en) 2005-04-08 2006-10-19 Chimerix, Inc. Compounds, compositions and methods for the treatment of poxvirus infections
US8524248B2 (en) 2007-12-14 2013-09-03 University of Pittsburgh—of the Commonwealth System of Higher Education Methods to diagnose and immunize against the virus causing human Merkel cell carcinoma
CN105055432A (zh) 2008-01-25 2015-11-18 奇默里克斯公司 治疗病毒感染的方法
WO2009111486A2 (en) * 2008-03-04 2009-09-11 The Regents Of The University Of California Reversing the immune decline of aging by a nutraceutical antioxidant in mice
US8614200B2 (en) 2009-07-21 2013-12-24 Chimerix, Inc. Compounds, compositions and methods for treating ocular conditions
AU2010313273B2 (en) * 2009-10-30 2015-04-02 Emergent Biodefense Operations Lansing Llc Methods of treating viral associated diseases
CA2789443C (en) 2010-02-12 2016-09-13 Chimerix, Inc. Nucleoside phosphonate salts
EP2563367A4 (en) 2010-04-26 2013-12-04 Chimerix Inc Methods of treating retroviral infections and related dosage regimes
CN105998039A (zh) * 2010-08-31 2016-10-12 奇默里克斯公司 膦酸酯衍生物及其合成方法
US20140303092A1 (en) * 2011-10-26 2014-10-09 Chimerix, Inc Hexadecyloxypropyl cidofovir for the treatment of double-stranded dna virus infection
CA2857490C (en) 2011-12-22 2020-03-31 Geron Corporation Guanine analogs as telomerase substrates and telomere length affectors
CN107312039B (zh) 2012-08-30 2019-06-25 江苏豪森药业集团有限公司 一种替诺福韦前药的制备方法
KR20150130355A (ko) * 2013-03-15 2015-11-23 더 리전트 오브 더 유니버시티 오브 캘리포니아 비환식 뉴클레오사이드 포스포네이트 디에스테르
US10221152B2 (en) * 2013-03-22 2019-03-05 Giant Force Technology Corporation Usage of mycophenolate mofetil or salt thereof in preparing drug for resisting against influenza virus
UA116825C2 (uk) 2013-11-15 2018-05-10 Чимерикс Інк. Морфологічні форми гексадецилоксипропілових складних ефірів фосфонової кислоти і способи їх синтезу
MX377983B (es) 2014-09-15 2025-03-04 Univ California Análogos de nucleótidos.
US10160778B2 (en) 2014-10-27 2018-12-25 Concert Pharmaceuticals, Inc. Pyrimidine phosphonic acid esters
GB201509431D0 (en) * 2015-06-01 2015-07-15 Equigerminal Sa Antiviral composition
EP3875462A1 (en) 2015-09-15 2021-09-08 The Regents of The University of California Nucleotide analogs
AU2017290703B2 (en) 2016-06-28 2023-03-30 Emergent Biodefense Operations Lansing Llc Formulations of brincidofovir
US12049474B2 (en) 2019-08-22 2024-07-30 Emory University Nucleoside prodrugs and uses related thereto
CN113288896A (zh) * 2021-05-28 2021-08-24 成都中医药大学 槐定碱在制备抗疱疹病毒的药物中的用途
KR20250052378A (ko) 2022-07-21 2025-04-18 안티바 바이오사이언시즈, 인크. Hpv 감염 및 hpv-유도 신생물의 치료를 위한 조성물 및 투여 형태
AU2022476501A1 (en) * 2022-08-31 2025-03-13 Symbio Pharmaceuticals Limited Pharmaceutical composition for treating lymphoma
JP7827310B2 (ja) * 2022-08-31 2026-03-10 シンバイオ製薬株式会社 リンパ腫の治療用医薬組成物
IL319274A (en) * 2022-08-31 2025-04-01 Symbio Pharmaceuticals Ltd Pharmaceutical preparation for the treatment of lymphoma
JPWO2024219491A1 (enExample) 2023-04-21 2024-10-24
WO2026100257A1 (ja) * 2024-11-05 2026-05-15 シンバイオ製薬株式会社 悪性腫瘍の治療
CN119080836B (zh) * 2024-11-07 2025-04-15 上海柯君医药科技有限公司 一种正痘病毒抑制剂及其应用

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA777769A (en) 1963-03-18 1968-02-06 H. Roy Clarence Substituted methylene diphosphonic acid compounds and detergent compositions
DE1248654B (de) 1964-11-11 1967-08-31 Albright & Wilson (Mf g) Limited, Oldbury, Warwickshire (Großbritannien) Verfahren zur Herstellung von Phosphonsäuren und deren Salzen
DE2943498C2 (de) 1979-10-27 1983-01-27 Henkel KGaA, 4000 Düsseldorf Verfahren zur Herstellung von 3-Amino-1-hydroxypropan-1,1-diphosphonsäure
US5047533A (en) 1983-05-24 1991-09-10 Sri International Acyclic purine phosphonate nucleotide analogs
IT1196315B (it) 1984-10-29 1988-11-16 Gentili Ist Spa Procedimento per la preparazione di acidi difosfonici
IL77243A (en) 1984-12-21 1996-11-14 Procter & Gamble Pharmaceutical compositions containing geminal diphosphonic acid compounds and certain such novel compounds
GB8530603D0 (en) 1985-12-12 1986-01-22 Leo Pharm Prod Ltd Chemical compounds
DE3623397A1 (de) 1986-07-11 1988-01-14 Boehringer Mannheim Gmbh Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel
CS264222B1 (en) 1986-07-18 1989-06-13 Holy Antonin N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them
US5247085A (en) 1987-11-30 1993-09-21 Beecham Group P.L.C. Antiviral purine compounds
SU1548182A1 (ru) 1987-12-29 1990-03-07 Институт молекулярной биологии АН СССР 5 @ -Фосфонаты 3 @ -азидо-2 @ ,3 @ -дидезоксинуклеозидов, вл ющиес специфическими ингибиторами вируса СПИД в культуре лимфоцитов человека Н9/ШВ
IL91362A0 (en) 1989-08-20 1990-03-19 Yissum Res Dev Co Bisphosphonates,process for preparing them and pharmaceutical compositions containing them
US5196409A (en) 1989-08-20 1993-03-23 Yissum, Research Development Company Of The Hebrew University Of Jerusalem Bisphosphonates, pharmaceutical compositions, and process for the treatment of irregularities in calcium metabolism
IT1241674B (it) 1989-10-12 1994-01-27 Boehringer Biochemia Srl Acidi gem-difosfonici, un processo per la loro preparazione e composizioni farmaceutiche che li contengono.
US5039819A (en) 1990-09-18 1991-08-13 Merck & Co., Inc. Diphosphonate intermediate for preparing an antihypercalcemic agent
FI89365C (fi) 1990-12-20 1993-09-27 Leiras Oy Foerfarande foer framstaellning av nya farmakologiskt anvaendbara metylenbisfosfonsyraderivat
US5183815A (en) 1991-01-22 1993-02-02 Merck & Co., Inc. Bone acting agents
US5672697A (en) 1991-02-08 1997-09-30 Gilead Sciences, Inc. Nucleoside 5'-methylene phosphonates
US5300687A (en) 1991-07-18 1994-04-05 Ortho Pharmaceutical Corporation Trifluoromethylbenzylphosphonates useful in treating osteoporosis
US5270365A (en) 1991-12-17 1993-12-14 Merck & Co., Inc. Prevention and treatment of periodontal disease with alendronate
JP3141053B2 (ja) 1991-12-26 2001-03-05 アベンティス ファーマ株式会社 ビスホスホン酸誘導体
EP0642521A1 (en) 1992-05-29 1995-03-15 Procter & Gamble Pharmaceuticals Thio-substituted nitrogen-containing heterocyclic phosphonate compounds for treating abnormal calcium and phosphate metabolism
ES2129485T3 (es) 1992-12-02 1999-06-16 Hoechst Ag Derivados de acidos guanidinoalquil-1,1-bisfosfonicos, procedimiento para su preparacion y su utilizacion.
US5817647A (en) 1993-04-01 1998-10-06 Merrell Pharmaceuticals Inc. Unsaturated acetylene phosphonate derivatives of purines
CA2171868A1 (en) 1993-09-17 1995-03-23 Petr Alexander Method for dosing therapeutic compounds
US5798340A (en) 1993-09-17 1998-08-25 Gilead Sciences, Inc. Nucleotide analogs
US5656745A (en) 1993-09-17 1997-08-12 Gilead Sciences, Inc. Nucleotide analogs
US5441946A (en) 1994-04-14 1995-08-15 Rhone-Poulenc-Rorer Pharmaceuticals, Inc. Phosphonate derivatives of lipophilic amines
EP0753523A1 (en) 1995-07-10 1997-01-15 Gador S.A. Amino-substituted bisphosphonic acids
US5885973A (en) 1995-12-27 1999-03-23 Gador, S.A. Bone mass anabolic composition comprising olpadronate
US5717095A (en) 1995-12-29 1998-02-10 Gilead Sciences, Inc. Nucleotide analogs
TW369536B (en) 1996-01-18 1999-09-11 Mitsubishi Chem Corp Phosphonate nucleotide compounds
US5877166A (en) 1996-04-29 1999-03-02 Sri International Enantiomerically pure 2-aminopurine phosphonate nucleotide analogs as antiviral agents
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5760013A (en) 1996-08-21 1998-06-02 National Science Council Thymidylate analogs and the use thereof
CA2300957A1 (en) * 1997-08-15 1999-02-25 Rubicon Laboratory, Inc. Retrovirus and viral vectors
WO2001022950A2 (en) 1999-09-24 2001-04-05 Shire Biochem Inc. Diosolane nucleoside analogs for the treatment or prevention of viral infection
US6716825B2 (en) 1999-12-03 2004-04-06 The Regents Of The University Of California Phosphonate compounds
US20050187192A1 (en) * 2004-02-20 2005-08-25 Kucera Pharmaceutical Company Phospholipids for the treatment of infection by togaviruses, herpes viruses and coronaviruses
TW200714289A (en) * 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
WO2006110655A2 (en) 2005-04-08 2006-10-19 Chimerix, Inc. Compounds, compositions and methods for the treatment of poxvirus infections
US20070072831A1 (en) 2005-05-16 2007-03-29 Gilead Sciences, Inc. Integrase inhibitor compounds
ES2600792T3 (es) * 2006-05-03 2017-02-10 Chimerix, Inc. Alcoxialquilésteres metabólicamente estables de fosfonatos, fosfonatos nucleosídicos y fosfatos nucleosídicos antivirales o antiproliferativos
CN101678122A (zh) * 2007-04-27 2010-03-24 奇默里克斯公司 在核苷给药的受体中降低肾中毒性的方法
US20090111774A1 (en) * 2007-06-01 2009-04-30 Luitpold Pharmaceuticals, Inc. Pmea lipid conjugates

Similar Documents

Publication Publication Date Title
JP6875454B2 (ja) Hivを治療するためのトール様受容体の調節因子
JP2009528369A5 (enExample)
JP2013543501A5 (enExample)
US10441589B2 (en) Combinations and methods comprising a capsid assembly inhibitor
US20100227801A1 (en) Pharmaceutical compositions
JP2017527532A5 (enExample)
JP2022009683A (ja) テノホビルアラフェナミドの結晶形態
JP2015506348A5 (enExample)
JP2014506321A5 (enExample)
JP2019515908A5 (enExample)
JP2014504643A5 (enExample)
JP2010514834A5 (enExample)
JP2023526754A (ja) Covid および covid-19 の予防と治療の方法
CN115605194A (zh) 过度炎症综合征的治疗
JP2023531930A5 (enExample)
JP2022514561A5 (enExample)
US9872895B2 (en) TLR5 ligands, therapeutic methods, and compositions related thereto
KR20180058659A (ko) 에베롤리무스와 닥톨리십의 약제학적 병용물
JP2017508737A5 (enExample)
CA3176642A1 (en) Cysteamine for the treatment of sars-cov-2 infection
WO2012061060A1 (en) Use of teriflunomide for treating brain atrophy
JP2014524450A5 (enExample)
AU2013311025A1 (en) Combination of a macrocyclic protease inhibitor of HCV, a non-nucleoside HCV inhibitor and ritonavir
JP2023500352A (ja) 移植片対宿主病を予防又は治療するための化合物
JP2017514834A (ja) Hcv感染症を治療するための組合せ療法